Registry of Lipid Control and the Use of Lipid-lowering Drugs for Secondary Prevention of Cardiovascular Events in Patients with Established Atherosclerotic Disease in Taiwan: Rationality and Methods
Background: Dyslipidemia is an important but modifiable risk factor of cardiovascular disease (CVD). However, no nationwide registry has been designed so far to document the inter-relationship between long-term clinical outcomes and the lipid control, and the use of lipid-lowering agents for seconda...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taiwan Society of Geriatric Emergency and Critical Medicine (TSGECM)
2012-12-01
|
Series: | International Journal of Gerontology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S187395981200107X |
id |
doaj-44751f5397fb4594a2a33f8dc250c557 |
---|---|
record_format |
Article |
spelling |
doaj-44751f5397fb4594a2a33f8dc250c5572020-11-25T01:01:13ZengTaiwan Society of Geriatric Emergency and Critical Medicine (TSGECM)International Journal of Gerontology1873-95982012-12-016424124610.1016/j.ijge.2012.09.001Registry of Lipid Control and the Use of Lipid-lowering Drugs for Secondary Prevention of Cardiovascular Events in Patients with Established Atherosclerotic Disease in Taiwan: Rationality and MethodsWei-Hsian Yin0Chau-Chung Wu1Jaw-Wen Chen2Division of Cardiology, Heart Centre, Cheng-Hsin General Hospital, Taipei, TaiwanDivision of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, TaiwanDepartment of Medical Research and Education, Taipei Veterans General Hospital, Taipei, TaiwanBackground: Dyslipidemia is an important but modifiable risk factor of cardiovascular disease (CVD). However, no nationwide registry has been designed so far to document the inter-relationship between long-term clinical outcomes and the lipid control, and the use of lipid-lowering agents for secondary prevention of cardiovascular events in patients with established CVD in a large representative sample of public and private hospitals in Taiwan. Methods: In this registry-type prospective observational study, we sought to record information with regard to the secondary prevention of patients with stable symptomatic atherosclerotic disease, classified by the presence of one of the following conditions: evidence of coronary artery disease, cerebrovascular disease, or peripheral vascular disease, focusing on lipid management, and long-term outcomes. The data on customary Taiwanese clinical practice applied to outpatients will be collected from 14 centers across Taiwan, including public and private hospitals, and will be clinically followed for 5 years after their inclusion. Results: The analysis of this multicenter registry will demonstrate the treatment patterns, goal attainment, factors influencing treatment, and the clinical outcomes among patients suffering from CVD in Taiwan. Conclusions: The registry may increase our understanding of the prevalence and consequences of atherothrombosis on a nationwide basis. In addition to academic interests, the results may have impact on future clinical practice pattern and national policy on lipid management in Taiwan.http://www.sciencedirect.com/science/article/pii/S187395981200107Xatherosclerosiscardiovascular diseaseslipid-lowering drugslipid managementrisk factors |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Wei-Hsian Yin Chau-Chung Wu Jaw-Wen Chen |
spellingShingle |
Wei-Hsian Yin Chau-Chung Wu Jaw-Wen Chen Registry of Lipid Control and the Use of Lipid-lowering Drugs for Secondary Prevention of Cardiovascular Events in Patients with Established Atherosclerotic Disease in Taiwan: Rationality and Methods International Journal of Gerontology atherosclerosis cardiovascular diseases lipid-lowering drugs lipid management risk factors |
author_facet |
Wei-Hsian Yin Chau-Chung Wu Jaw-Wen Chen |
author_sort |
Wei-Hsian Yin |
title |
Registry of Lipid Control and the Use of Lipid-lowering Drugs for Secondary Prevention of Cardiovascular Events in Patients with Established Atherosclerotic Disease in Taiwan: Rationality and Methods |
title_short |
Registry of Lipid Control and the Use of Lipid-lowering Drugs for Secondary Prevention of Cardiovascular Events in Patients with Established Atherosclerotic Disease in Taiwan: Rationality and Methods |
title_full |
Registry of Lipid Control and the Use of Lipid-lowering Drugs for Secondary Prevention of Cardiovascular Events in Patients with Established Atherosclerotic Disease in Taiwan: Rationality and Methods |
title_fullStr |
Registry of Lipid Control and the Use of Lipid-lowering Drugs for Secondary Prevention of Cardiovascular Events in Patients with Established Atherosclerotic Disease in Taiwan: Rationality and Methods |
title_full_unstemmed |
Registry of Lipid Control and the Use of Lipid-lowering Drugs for Secondary Prevention of Cardiovascular Events in Patients with Established Atherosclerotic Disease in Taiwan: Rationality and Methods |
title_sort |
registry of lipid control and the use of lipid-lowering drugs for secondary prevention of cardiovascular events in patients with established atherosclerotic disease in taiwan: rationality and methods |
publisher |
Taiwan Society of Geriatric Emergency and Critical Medicine (TSGECM) |
series |
International Journal of Gerontology |
issn |
1873-9598 |
publishDate |
2012-12-01 |
description |
Background: Dyslipidemia is an important but modifiable risk factor of cardiovascular disease (CVD). However, no nationwide registry has been designed so far to document the inter-relationship between long-term clinical outcomes and the lipid control, and the use of lipid-lowering agents for secondary prevention of cardiovascular events in patients with established CVD in a large representative sample of public and private hospitals in Taiwan.
Methods: In this registry-type prospective observational study, we sought to record information with regard to the secondary prevention of patients with stable symptomatic atherosclerotic disease, classified by the presence of one of the following conditions: evidence of coronary artery disease, cerebrovascular disease, or peripheral vascular disease, focusing on lipid management, and long-term outcomes. The data on customary Taiwanese clinical practice applied to outpatients will be collected from 14 centers across Taiwan, including public and private hospitals, and will be clinically followed for 5 years after their inclusion.
Results: The analysis of this multicenter registry will demonstrate the treatment patterns, goal attainment, factors influencing treatment, and the clinical outcomes among patients suffering from CVD in Taiwan.
Conclusions: The registry may increase our understanding of the prevalence and consequences of atherothrombosis on a nationwide basis. In addition to academic interests, the results may have impact on future clinical practice pattern and national policy on lipid management in Taiwan. |
topic |
atherosclerosis cardiovascular diseases lipid-lowering drugs lipid management risk factors |
url |
http://www.sciencedirect.com/science/article/pii/S187395981200107X |
work_keys_str_mv |
AT weihsianyin registryoflipidcontrolandtheuseoflipidloweringdrugsforsecondarypreventionofcardiovasculareventsinpatientswithestablishedatheroscleroticdiseaseintaiwanrationalityandmethods AT chauchungwu registryoflipidcontrolandtheuseoflipidloweringdrugsforsecondarypreventionofcardiovasculareventsinpatientswithestablishedatheroscleroticdiseaseintaiwanrationalityandmethods AT jawwenchen registryoflipidcontrolandtheuseoflipidloweringdrugsforsecondarypreventionofcardiovasculareventsinpatientswithestablishedatheroscleroticdiseaseintaiwanrationalityandmethods |
_version_ |
1725210126498922496 |